Editas Medicine, Inc. (EDIT) incurred a loss of 76 cents per share in the first quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 63 cents. The company had reported a loss of 71 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $1.1 million in the first quarter, down from$9.8 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $12 million. ...